These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Leucht S. Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080 [Abstract] [Full Text] [Related]
3. How do we choose between atypical antipsychotics? The advantages of amisulpride. Mortimer AM. Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S21-5. PubMed ID: 14972081 [Abstract] [Full Text] [Related]
10. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Danion JM, Rein W, Fleurot O. Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742 [Abstract] [Full Text] [Related]
14. Amisulpride: a review of its use in the management of schizophrenia. McKeage K, Plosker GL. CNS Drugs; 2004 Apr; 18(13):933-56. PubMed ID: 15521794 [Abstract] [Full Text] [Related]
15. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Bhowmick S, Hazra A, Ghosh M. Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717 [Abstract] [Full Text] [Related]
16. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature. Zink M, Knopf U, Henn FA, Thome J. Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045 [Abstract] [Full Text] [Related]